Dr. Vinod Pullarkat, MD

Dr. Pullarkat practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Pullarkat's NPI, 1164433645, was assigned on August 10, 2006. Dr. Pullarkat holds California license A63417.

Dr. Pullarkat's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Pullarkat's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Pullarkat to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pullarkat practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Pullarkat's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Pullarkat is licensed in California.

CMS data shows 569 Medicare services from Dr. Pullarkat across 4 procedure codes in 2024, for 182 Medicare patients. Medicare paid $50,497 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 182 Medicare patients who saw Dr. Pullarkat in 2024. The largest group is 65 to 74, with 85 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 30% are also on Medicaid. Their average risk score is 3.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pullarkat's median patient age at 67, with 48% women.

In 2024, Dr. Pullarkat wrote 627 Medicare Part D claims for 115 patients. 56% of them were for generic drugs. CMS names the drug for 393 of them, across 11 drugs with 11 or more claims each, at $2,190,658 in total drug cost. In 2023, CMS named 532 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Pullarkat for performance year 2024, reported as part of a group. Dr. Pullarkat accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 161 papers to Dr. Pullarkat, published from 2010 to 2025. 2021 was the busiest year, with 19. The most frequent topics are Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma and Leukemia, Myeloid, Acute. Dr. Pullarkat has published most often in Am J Hematol. Dr. Pullarkat's most frequent co-authors are Guido Marcucci, MD, Anthony S. Stein, MD and Stephen J. Forman, MD.

Dmand AI links Dr. Pullarkat to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Thrombocythemia, Essential and Leukemia, Myeloid. AbbVie sponsors the most, 2. Open Payments lists research payments to Dr. Pullarkat that name 2 trials.

CMS Open Payments shows 857 general payments to Dr. Pullarkat from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Novartis Pharmaceuticals Corporation paid the most, $214,142. It also lists 15 research payments totaling $13,868 from 2016 to 2025, naming 2 clinical trials.